← Back to Stock Screener← Stock Screener

ZYBERNO

Stock Report

Updated Aug 29, 2026

Ascendis Pharma A/S (ASND)

Healthcare • NASDAQ

$247.08

Ascendis Pharma A/S is a Danish biopharmaceutical company headquartered in Hellerup, Denmark, that uses its TransCon technology platform to develop prodrugs that release an unmodified parent drug in a predictable manner. The company's lead product Skytrofa (TransCon hGH) is approved for pediatric growth hormone deficiency, and it has a pipeline of TransCon therapies for endocrinology and oncology conditions.

Professional Investment Analysis

ZYBERNO SCORE →

Is it a great business? Is it getting better?

27.0/100

POOR BUSINESS

Ascendis Pharma A/S (ASND) scores 27/100 — concerning metrics indicating significant structural or financial risks.

📊 How is the Zyberno Score calculated? +

The Zyberno Score answers one question: "Is this a quality business worth owning?" It's a 0-100 investment grade that evaluates business fundamentals across four critical dimensions, based on principles from Warren Buffett, Benjamin Graham, Peter Lynch, and Charlie Munger.

The 4 Core Categories (25 points each):

1. PROFITABILITY (25 pts)

Metrics: ROE, ROIC, Net Margin, Operating Margin
Thresholds: ROE >20% excellent • ROIC >20% excellent • Net Margin >20% excellent • Operating Margin >25% excellent

2. FINANCIAL STRENGTH (25 pts)

Metrics: Debt-to-Equity, Current Ratio, Interest Coverage, Altman Z-Score
Thresholds: D/E <0.3 excellent • Current Ratio >2.5 excellent • Interest Coverage >10x excellent • Altman Z >3.0 safe

3. CASH FLOW QUALITY (25 pts)

Metrics: Free Cash Flow, OCF vs Net Income, FCF Margin
Thresholds: Positive & growing FCF excellent • OCF/NI >1.2x excellent (cash earnings exceed accounting)

4. GROWTH & CONSISTENCY (25 pts)

Metrics: Revenue Growth, Net Income Growth, FCF Growth, Piotroski F-Score
Thresholds: Growth via log-linear regression • Piotroski 8-9 excellent, 6-7 good

Score Interpretation:

75-100

GREAT BUSINESS

65-74

GOOD BUSINESS

50-64

AVERAGE BUSINESS

30-49

WEAK BUSINESS

0-29

POOR BUSINESS

→ View full ASND quality analysis & detailed breakdown

VALUATION SIGNAL

N/A (Requires more data)

Requires fair value calculation and current price data

💰 How is Margin of Safety calculated? +

Margin of Safety measures how much discount or premium you're paying relative to a stock's intrinsic value. It's Benjamin Graham's core principle: the larger the margin, the lower your downside risk.

Formula: (Intrinsic Value − Current Price) ÷ Intrinsic Value × 100%

How We Calculate Intrinsic Value (DCF Method):

Step 1: Calculate current Owner Earnings (OCF − Maintenance CapEx)

Step 2: Calculate company-specific growth rate using log-linear regression on 16 quarters of Owner Earnings

Step 3: Project 10 years forward using the calculated growth rate

Step 4: Discount each year's cash flow to present value using 10% discount rate

Step 5: Calculate terminal value using 3% perpetual growth rate

Step 6: Sum all discounted cash flows = Intrinsic Value

What The Percentages Mean:

+50% or more

EXCELLENT — Very undervalued

+25% to +50%

GOOD — Attractive discount

0% to +25%

FAIR — Reasonable value

0% to -25%

CAUTION — Slight premium

-25% or worse

POOR — Overvalued

"Price is what you pay, value is what you get." — Warren Buffett

→ View full ASND valuation analysis · → View full ASND Brina Gap analysis

📈 How is Brina Gap calculated? +

Brina Gap measures the difference between the growth a business can fundamentally sustain and the growth the market is already pricing in.

Formula: Fundamental Growth Rate − Market-Implied Growth Rate

The Two Components:

Fundamental Growth Rate = ROIC × Reinvestment Rate

What the business can sustainably grow at based on how much it reinvests and what return it earns on that capital. Grounded in historical financials.

Market-Implied Growth Rate = Reverse DCF

The growth rate the current Enterprise Value implicitly assumes. Calculated by back-solving a 10-year DCF model (10% WACC, 3% terminal growth) until the present value of projected cash flows equals EV.

What The Gap Means:

Gap > +5% Market Underestimates — potential upside

+2% to +5% Slight Underestimate

-2% to +2% Fairly Priced — market consensus matches fundamentals

-5% to -2% Slight Overestimate

Gap < -5% Market Overestimates — price embeds optimism fundamentals don't support

A positive gap (market underestimates) combined with a positive Margin of Safety is the strongest combined signal — the business is both cheap historically and forward economics are stronger than the price suggests.

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)

Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)

Operating Margin (Operational Efficiency):CRITICAL (-18.9%)

Return on Capital (Capital Efficiency):CRITICAL (-285.6%)

📊 Valuation Trilogy

Three interconnected metrics for complete valuation analysis

Click any metric for full methodology and detailed analysis

Zyberno's Verdict

Ascendis Pharma A/S (ASND) stock report — Zyberno Score 27/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY

A. Market Valuation

Market Price & Capitalization (2)

Current Price:247.08

Market Cap:$15.31B

Valuation Multiples (2)

P/S Ratio:18.40x

Peg Ratio:-999.00x

Enterprise Metrics (2)

Enterprise Value:$15.54B

Pfcf Ratio:257.58x

Price Action & Momentum (3)

12-1 Momentum:

+46.3% (83th pctile)

📈 Click to view full ASND Momentum analysis →

Momentum Percentile:83 / 100

% of 52-Week High:87.6%

B. Profitability Assessment

Return Metrics (4)

ROA:-17.5%

Roic:

-285.6%

📊 Click to view full ASND ROIC analysis →

Reinvestment Rate:-2.4%

Fundamental Growth Rate (g):6.8%

Margin Analysis (3)

Operating Margin Ttm:-18.9%

Net Margin Ttm:-31.7%

Ebitda Margin:-18.9%

TTM Performance (3)

Gross Margin Ttm:86.8%

Operating Margin Ttm:-18.9%

Net Margin Ttm:-31.7%

Yield Metrics (2)

Earnings Yield:-$2.35

Dividend Yield:0.0%

C. Log-Linear Regression Growth Trends

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):100.0%

D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.04x

Quick Ratio:0.76x

Cash Ratio:0.58x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-0.66x

Times Interest Earned:-0.66

Capital Structure (4)

Working Capital:45,746,907.60

Cash And Cash Equivalents:711,773,771.40

Long Term Debt:$445.12M

Net Debt:$229.47M

DIVISION II: FINANCIAL STATEMENTS ANALYSIS

A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $832.04M

Linear Growth: 100.0%

📊 Click to view full ASND Revenue analysis & methodology →

Cost Of Revenue Ttm:$109.66M

Profitability Breakdown (2)

Gross profit TTM: $722.38M

Linear Growth: 100.0%

📊 Click to view full ASND Gross Profit analysis & methodology →

-$157.45M

Bottom Line Performance (3)

-$263.47M

Income Before Tax:$0.00

Ebitda Ttm:-157,447,513.40

Operating Expenses (5)

Operating Expenses:0.00

R And D Expense:0.00

Sga Expense:0.00

Income Tax Expense:$17.77M

Interest Expense:238,806,159.80

Expense Ratios (3)

R And D To Revenue Percentage:0.0%

Sga To Revenue Percentage:0.0%

Ebitda Margin:-18.9%

B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$1.50B

Current Assets:$1.28B

Ppe Net:169,241,836.60

Goodwill:4,038,123.00

Intangible Assets:$4.29M

Liability Structure (4)

Total Liabilities:1,693,112,761.40

Current Liabilities:1,235,574,361.40

Long Term Debt:$445.12M

Short Term Debt:$496.12M

Equity & Capital (3)

Equity:-$188.12M

Retained Earnings:$0.00

Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:0.00

Inventory:348,391,228.20

Accounts Payable:104,745,097.80

Special Items (2)

Contract Liabilities:0.00

Stock Based Compensation:0.00

C. Cash Flow Analysis

Operating Activities (2)

$62.27M$59.45M

Investment Activities (1)

Investing Cash Flow:-$812.25K

Financing Activities (3)

Financing Cash Flow:-$20.82M

Dividends Paid Ttm:0.00

Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00

Long Term Debt Issuance:$0.00

Long Term Debt Repayments:$0.00

DIVISION III: OPERATIONAL METRICS

A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-3.76

-$5.81

Earnings Per Share Ttm:-$4.25

Revenue & Cash Per Share (2)

Sales Per Share Ttm:13.42

Operating Cash Flow Per Share:$1.00

Book Value & Capital (2)

Book Value Per Share:-$3.04

Cash Per Share:11.48

Dividend Policy (1)

Dividend Payout Ratio:-999.00x

B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.55x

Working Capital Turnover Ttm:18.19x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x

Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:0.31x

Days Inventory Outstanding Ttm:1,159.56

Payables & Cash Cycle (2)

Days Payable Outstanding:348.63

Cash Conversion Cycle:-188.07

C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00

Quality Score:35.00

Market Metrics (2)

Beta:0.00x

Volatility Category:unknown

DIVISION IV: INVESTMENT ANALYSIS

A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-2.4%

Fundamental Growth Rate (g):6.8%

B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):100.0%

Other Growth Rates (1)

Gross Profit Growth Rate (Linear):100.0%

C. Company Profile & Context

Corporate Information (6)

Symbol:ASND

Company Name:Ascendis Pharma A/S

Sector:Healthcare

Industry:Pharmaceuticals

Exchange:NASDAQ

Country:United States

Market Classification (3)

Market Cap Category:N/A

Price Category:premium

Volume Category:N/A

Share Structure (3)

Shares Outstanding:61.98M

Shares Outstanding Basic:0

Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0

Last Updated:2026-08-29 08:10:57 UTC

Data Timestamp:2026-08-29T08:10:57.100603